Literature DB >> 7448765

Correlation of growth properties and morphology with hormone responsiveness of mammary tumor cells in culture.

J Yates, R J King.   

Abstract

A cell line derived from the androgen-responsive Shionogi 115 mouse mammary carcinoma is being used to investigate the changes in cell function accompanying steroid removal from steroid-responsive breast tumor cells. Shiongi 115 mouse mammary carcinoma cells become androgen unresponsive after two weeks of culture in the absence of testosterone although androgen receptors are still present in the cytoplasm and nucleus. Androgen-responsive cells are fibroblastic in appearance, have a low serum requirement, and can proliferate in suspension culture. Unresponsive cells, however, show a flattened morphology, are serum sensitive, and are anchorage dependent. As the androgen receptor mechanism of the unresponsive cells is intact, loss of sensitivity may be caused by a postreceptor defect. To determine the nature of this defect, the temporal relationships of changes in hormone responsiveness, morphology, serum sensitivity, and growth properties have been examined over a period of seven weeks following removal of testosterone from Shionogi 115 mouse mammary carcinoma cell cultures. Responses to testosterone and anchorage independence are both lost over a period of one to two weeks while serum sensitivity increases more slowly during the same period. The most rapid and least reversible change is seen in morphology. It is suggested that hormone responsiveness is related to properties of the cytoskeleton and cell membrane which influence growth rates and multiple sensitivities of tumor cells.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7448765

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  10 in total

1.  Conserved molecular mechanisms underlying the effects of small molecule xenobiotic chemotherapeutics on cells.

Authors:  Hemant Sarin
Journal:  Mol Clin Oncol       Date:  2015-12-16

2.  Steroid-induced epithelial-fibroblastic conversion associated with syndecan suppression in S115 mouse mammary tumor cells.

Authors:  S Leppä; P Härkönen; M Jalkanen
Journal:  Cell Regul       Date:  1991-01

3.  The influence of a novel cyclopropyl antiestrogen (compound 7a) on human breast cancer cells in culture.

Authors:  P T Jain; J T Pento; R A Magarian
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

4.  Phenotypic stability of mouse mammary tumor cells cultured on collagen gels.

Authors:  J T Emerman; A J Worth
Journal:  In Vitro Cell Dev Biol       Date:  1985-01

5.  Proliferation of a highly androgen-sensitive ductus deferens cell line (DDT1MF-2) is regulated by glucocorticoids and modulated by growth on collagen.

Authors:  A J Syms; J S Norris; R G Smith
Journal:  In Vitro       Date:  1983-12

6.  Syndecan expression regulates cell morphology and growth of mouse mammary epithelial tumor cells.

Authors:  S Leppä; M Mali; H M Miettinen; M Jalkanen
Journal:  Proc Natl Acad Sci U S A       Date:  1992-02-01       Impact factor: 11.205

7.  Relapse of androgen-dependent tumour of mouse (Shionogi Carcinoma 115) after castration and oestrogen treatment.

Authors:  T Miyauchi; M Wakisaka; S Hara; O Matsuzaki; J Shimazaki
Journal:  Urol Res       Date:  1983

8.  Dexamethasone modulation of in vitro growth pattern and of lung colonization ability in clones of a metastatic BALB/c mammary carcinoma cell line.

Authors:  C De Giovanni; P L Lollini; G Nicoletti; S Grilli; G Prodi; P Nanni
Journal:  Clin Exp Metastasis       Date:  1986 Jan-Mar       Impact factor: 5.150

9.  Progression to steroid autonomy in S115 mouse mammary tumor cells: role of DNA methylation.

Authors:  P Darbre; R J King
Journal:  J Cell Biol       Date:  1984-10       Impact factor: 10.539

10.  Progression of androgen-sensitive mouse tumor (Shionogi carcinoma 115) to androgen-insensitive tumor after long-term removal of testosterone.

Authors:  N Sato; Y Watabe; H Suzuki; J Shimazaki
Journal:  Jpn J Cancer Res       Date:  1993-12
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.